Generics for Janumet competition begins in earnest in Oct.

A large number of salt-modifying complex drugs are listed

Chong Kun Dang and Hanmi are the first to sell in the September market

MSD DPP-4 inhibitory diabetes treatment

The diabetes treatment market is expected to remain active in October.

 

This is because salt-modifying complex drugs that were not registered in September are hitting the market all at once.

 

According to the industry on the 20th, generics of MSD's DPP-4 inhibitory diabetes combination drug 'Janumet and Janumet XR' will be listed in large numbers next month.

 

These are salt-modifying drugs, and due to the calculation criteria, they were not released when the patent expired on September 2nd.

 

This is because salt-modified complex drugs can only be calculated if a single salt-modified drug with the same ingredient is registered first.

 

Sitagliptin hydrochloride hydrate complex drugs are scheduled to be registered in October.

 

On the 2nd of this month, 134 single products were registered.

 

There are 304 combination drugs on the approved list that combine Sitagliptin HCl and Metformin.

 

If there are no production issues, most of these are expected to be registered in October.

 

A combination drug combining Sitagliptin phosphate and Metformin is expected to be released in October.

 

Accordingly, the follow-up drugs of Janumet and Janumet XR are expected to enter into full-scale competition starting in October.

 

Looking at last year's outpatient prescriptions based on UBIST, Januvia's single drug was 40.5 billion won, Janumet and Janumet XR combination drugs were 68.9 billion won and 48.2 billion won, respectively, totaling 117.1 billion won, forming a much larger market than single drugs.

 

The key appears to be the speed with which Hanmi Pharmaceutical and Chong Kun Dang can dominate the market.

 

Both companies were the only ones to list Janumet and Janumet XR generics on September 2nd.

 

This was possible because only both companies obtained generic for exclusivity as a generic with the same ingredient.

 

The entry speed of other generics is expected to be determined by how well the two companies with large sales forces dominate the market within a month.

 

An official in the pharmaceutical industry said, "In the Janumet and Janumet XR generics market, only Hanmi and Chong Kun Dang had the opportunity to dominate the market due to the salary standards, and other generic companies entered the market a month late." He explained, “The key for other generic companies is how much of the overall market share the two companies that released a month early have taken.”